Serial Measurement of Capillary Blood Lactate in the Management of Sepsis

Role of the Serial Measurement of Capillary Blood Lactate in the Management of Sepsis Outside the Intensive Care

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02180399

Acronym

SepsisMI

Enrollment

Registered

2014-07-02

Start date

2014-02-28

Completion date

2017-09-30

Last updated

2025-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

Sepsis, Capillary blood lactate, Serial measurement of capillary

Brief summary

Determination of capillary lactate by using point-of-care technique is accessible, fast and allows to quantify the circulatory and metabolic dysfunction caused by sepsis. Compared to conventional assay techniques in arterial blood, capillary assay technique may have an increased susceptibility to metabolic alterations induced by sepsis in its initial stages. This increased sensitivity is not necessarily relevant in the management of the most serious patients for whom the diagnosis is obvious, but it could be very useful in patients for whom a diagnosis of severe sepsis or shock have not yet been adopted, particularly to help better identify patients who would require intensive management and avoid the installation of these serious disorders.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥ 18 years * Installation without any plausible explanation of at least one of the following clinical criteria: * Chills, fever, mottling, respiratory rate\> 20/min; Sat02 \< 90% or \> 94% with more than 4l O2, heart rate \> 90/min,systolic blood pressure \< 100 mmHg or 40 mmHg lower compared with normal values, Glasgow coma score \< 14. or: .a combination of two (or more) of clinical and laboratory criteria for sepsis. * Signed informed consent form

Exclusion criteria

* Need in its current treatment of aerosol administration of beta agonists at a frequency greater than one per 8 hours; * Targeted therapeutic measures have already stated for more than 60 minutes; * Diagnosis other than Sepsis; * Malignant neoplasm or other progressive disease and expected survival was less than 3 months.

Design outcomes

Primary

Measure	Time frame
measurement of capillary blood lactate	72 hours after inclusion

Countries

France

Outcome results